Leading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality Disorder (BPD) CAB and Oryzon establish primary and ...

Discover why decades of research now challenge the BPD diagnosis — and how new models may offer clearer, less stigmatizing ways forward.

Oryzon Genomics will seek the FDA’s advice after a psychiatric drug failed to impact the symptoms or severity of borderline personality disorder, but executives are keen to push forward with refreshed ...

Agitation-Aggression in Borderline Personality Disorder (BPD) acknowledged as a possible therapeutic indication Oryzon may use STAXI-2 Trait anger as a primary efficacy endpoint for PORTICO-2 ...

Individuals with BPD have a very fragile sense of self. They tend to view themselves as victims and expect others to hurt and reject them. They crave support and a sense of belonging yet inadvertently ...